{
  "abstract": "Individuals with HIV/hepatitis C virus (HCV) coinfection and advanced liver disease remain at risk of hepatocellular carcinoma (HCC) despite curative direct-acting antiviral (DAA) therapy. The HepCAUSAL Collaboration is a European and North American multi-centre cohort of 20 289 individuals with HIV/HCV coinfection. This modelling study estimated the 6-year HCC risk under a hypothetical scenario in which all individuals with advanced fibrosis or cirrhosis received DAAs. A total of 3824 DAA-naïve individuals with virologically suppressed HIV and a current HCV infection were followed for 6 years or until HCC diagnosis, death or loss to follow-up. Assuming all eligible participants initiated DAAs, modelling estimated a 6-year HCC risk of 2.5%. Risk was highest in the first year (0.8%) and lowest in the sixth year (0.1%). These findings support continued HCC surveillance, particularly in the early years after DAA therapy.",
  "authors": [
    {
      "affiliations": [
        "Institute for Global Health, University College London, London, UK"
      ],
      "name": "Marina Daskalopoulou"
    },
    {
      "affiliations": [
        "Infectious Diseases, Burjeel Hospital, Abu Dhabi, UAE"
      ],
      "name": "Rachel Herbert"
    },
    {
      "affiliations": [
        "Department of Genitourinary Medicine and Infectious Diseases, St. James’s Hospital, Dublin 8, Ireland"
      ],
      "name": "Giovanni Villa"
    },
    {
      "affiliations": [
        "Infectious Diseases Unit, University of Rome Tor Vergata, Roma, Italy"
      ],
      "name": "Drieda Zace"
    }
  ],
  "title": "Research news in clinical context",
  "uid": "dd515879-3e21-5871-9a65-34ff54bc25c7"
}